173 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
25 Apr 24
Other Events
8:30am
Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
8-K
EX-99.1
1yo5fg5
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
8-K
EX-99.1
s6izaiq6
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
EX-99.2
qm5ti
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
EX-99.1
dvj6hmlkuof6y4 2t
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
EX-99.2
vw4cap
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
485bzamqepozy 0n
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
6siorw4qp19p
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm
8-K
EX-99.1
8wgg 7wwf617
4 May 23
Blueprint Medicines Reports First Quarter 2023 Results
7:18am
8-K
EX-3.1
klx74oz94l
6 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:12pm